You are here

Article Text

Article menu
Download PDFPDF
Therapuetics
Review: pioglitazone does not reduce risk of mortality or cardiovascular events in type 2 diabetes

https://doi.org/10.1136/ebm.12.2.53

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Pioglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev 2006;(4):CD006060.

    
 
 Q In patients with type 2 diabetes, does pioglitazone reduce cardiovascular events, other adverse events, and mortality or improve health related quality of life?

    Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★★☆ Cardiology ★★★★★★☆ Endocrine ★★★★★★☆

    METHODS

    Embedded ImageData sources:

    Cochrane Library (issue 3, 2006), Medline, EMBASE/Excerpta Medica (to August 2006), Controlled Clinical Trials, and reference lists.

    Embedded ImageStudy selection and assessment:

    randomised controlled trials (RCTs) ⩾24 weeks in duration that evaluated pioglitazone in adults with type 2 diabetes. 22 RCTs (n = 12 466, mean age range 54–64 y) met the selection criteria: pioglitazone v placebo (4 RCTs) or another oral antidiabetic medication (13 RCTs), or pioglitazone combined with other oral medications or insulin v another combination of oral medications or insulin (7 RCTs). Assessment of methodological quality included randomisation method, allocation concealment, blinding, intention to treat analysis, and …

    View Full Text

    Footnotes

    • For correspondence: Dr B Richter, Universitaetsklinikum Duesseldorf, Duesseldorf, Germany. richterb{at}uni-duesseldorf.de

    • Source of funding: no external funding.